- Home
- MYO vs MRNS Comparison
MYO vs MRNS Comparison
Compare MYO & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- MRNS
- Stock Information
- Founded
- MYO 2004
- MRNS 2003
- Country
- MYO United States
- MRNS United States
- Employees
- MYO N/A
- MRNS N/A
- Industry
- MYO Industrial Specialties
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- MYO Health Care
- MRNS Health Care
- Exchange
- MYO Nasdaq
- MRNS Nasdaq
- Market Cap
- MYO 121.5M
- MRNS 104.7M
- IPO Year
- MYO 2017
- MRNS 2014
- Fundamental
- Price
- MYO $3.76
- MRNS $1.75
- Analyst Decision
- MYO Strong Buy
- MRNS Buy
- Analyst Count
- MYO 4
- MRNS 9
- Target Price
- MYO $7.63
- MRNS $9.75
- AVG Volume (30 Days)
- MYO 106.2K
- MRNS 563.7K
- Earning Date
- MYO 11-05-2024
- MRNS 11-05-2024
- Dividend Yield
- MYO N/A
- MRNS N/A
- EPS Growth
- MYO N/A
- MRNS N/A
- EPS
- MYO N/A
- MRNS N/A
- Revenue
- MYO $21,111,062.00
- MRNS $30,263,000.00
- Revenue This Year
- MYO $53.19
- MRNS $21.18
- Revenue Next Year
- MYO $39.01
- MRNS $56.42
- P/E Ratio
- MYO N/A
- MRNS N/A
- Revenue Growth
- MYO 21.22
- MRNS 16.56
- 52 Week Low
- MYO $1.06
- MRNS $1.05
- 52 Week High
- MYO $5.64
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- MYO 44.71
- MRNS 53.01
- Support Level
- MYO $3.63
- MRNS $1.72
- Resistance Level
- MYO $3.99
- MRNS $1.96
- Average True Range (ATR)
- MYO 0.17
- MRNS 0.10
- MACD
- MYO -0.01
- MRNS -0.01
- Stochastic Oscillator
- MYO 30.23
- MRNS 34.37
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.